Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

On-Line Patient Portal Use By Caregivers in Pediatric Oncology: Are We Widening Sociodemographic Disparities?

Corinna L Schultz, MD, Suzanne M McCahan, PhD, H. Timothy Bunnell, PhD, Fang Fang Chen, PhD, Melissa A Alderfer, PhD

Blood (2019) 134 (Supplement_1): 2131.

https://doi.org/10.1182/blood-2019-131543

Published: 2019

Journal Articles

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

Peter H. Cygan, MD, Sarah E. Arnold-Croop, MS, Elizabeth A. Weidman, BS, Fang Chen, PhD, Dajiang J. Liu, PhD, M. Elaine Eyster, MD, Laura Carrel, PhD

Blood (2019) 134 (Supplement_1): 1125.

https://doi.org/10.1182/blood-2019-126026

Published: 2019

Journal Articles

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3181.

https://doi.org/10.1182/blood.V130.Suppl_1.3181.3181

Published: 2017

Journal Articles

Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia A

Bhavya S Doshi, MD, Simon F Lacey, PhD BS, Fang Chen, PhD, Leslie J Raffini, MD MSCE, Valder R Arruda, MD PhD

Blood (2017) 130 (Supplement 1): 3677.

https://doi.org/10.1182/blood.V130.Suppl_1.3677.3677

Published: 2017

Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Blood (2017) 130 (Supplement 1): 505.

https://doi.org/10.1182/blood.V130.Suppl_1.505.505

Published: 2017

Journal Articles

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Simon F. Lacey, PhD, Pamela A Shaw, PhD, David T Teachey, MD, Scott L. Weiss, MD, Fang Chen, PhD, Vanessa E Gonzalez, M.B.A, Noelle Frey, MD MS, David L Porter, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Edward Pequignot, M.S., Carl H June, MD, Jan J. Melenhorst, PhD

Blood (2016) 128 (22): 2812.

https://doi.org/10.1182/blood.V128.22.2812.2812

Published: 2016

Journal Articles

Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia

Joseph A. Fraietta, PhD, Simon F. Lacey, PhD, Nicholas S Wilcox, Felipe Bedoya, PhD, Fang Chen, PhD, Elena Orlando, PhD, Jennifer L Brogdon, PhD, Wei-Ting Hwang, PhD, Noelle Frey, MD MS, Regina M Young, PhD, Edward Pequignot, M.S., David E Ambrose, BS, Bruce L Levine, PhD, Hans Bitter, PhD, David L Porter, MD, Jun Xu, PhD, Carl H June, MD, Jan Joseph Melenhorst, PhD

Blood (2016) 128 (22): 57.

https://doi.org/10.1182/blood.V128.22.57.57

Published: 2016

Journal Articles

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

Alfred L. Garfall, MD, Eric Lancaster, MD PhD, Edward A Stadtmauer, MD, Simon F. Lacey, PhD, Karen Dengel, BSN, RN, David E Ambrose, BS, Fang Chen, PhD, Minnal Gupta, MSc, Irina Kulikovskaya, PhD, Dan T. Vogl, MD, Gabriela Plesa, PhD, Brendan M Weiss, MD, Regina Ferthio, Celeste Richardson, PhD, Jan Joseph Melenhorst, PhD, Bruce L Levine, PhD, Carl H June, MD, Michael Milone, MD PhD, Adam D. Cohen, MD

Blood (2016) 128 (22): 5702.

https://doi.org/10.1182/blood.V128.22.5702.5702

Published: 2016

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Blood (2016) 128 (22): 1147.

https://doi.org/10.1182/blood.V128.22.1147.1147

Published: 2016

Journal Articles

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

Blood (2016) 128 (22): 974.

https://doi.org/10.1182/blood.V128.22.974.974

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

Journal Articles

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

David T Teachey, MD, Simon F. Lacey, PhD BSc, Pamela A Shaw, PhD, J Joseph Melenhorst, PhD, Noelle V. Frey, MD, Shannon L Maude, MD PhD, David M. Barrett, MD PhD, Richard Aplenc, MD PhD, Fang Chen, PhD, Julie Fitzgerald, MD PhD, Vanessa Gonzalez, M.B.A, Edward Pequignot, PhD, Susan R. Rheingold, MD, Scott Weiss, MD, Jason C. White, DO, Carl H. June, MD, David L. Porter, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 1334.

https://doi.org/10.1182/blood.V126.23.1334.1334

Published: 2015

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

NARROW

On-Line Patient Portal Use By Caregivers in Pediatric Oncology: Are We Widening Sociodemographic Disparities?

Bleeding in Mild Hemophilia A Due to a Splice-Site F8 Mutation May be Fully Abrogated By Prothrombotic Gene Variants

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Novel Correlation between B Cell Survival Cytokines and Inhibitors in Hemophilia A

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only